Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
26.45
-1.95 (-6.88%)
Jul 24, 2026, 4:00 PM EDT - Market closed

Pelthos Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
27.716.8----
Revenue Growth
------
Gross Profit
20.8211.58-1.18--0.39-0.21
Operating Income
-42.66-31.41-7.57-6.86-2.32-0.84
Net Income
-51.59-43.32-7.96-7.38-2.46-0.6
Earnings Per Share
-20.19-23.04-14.27-57.82-56.48-
EPS Growth
------

Revenue by Segment

Fiscal YearFY 2025
Period EndingDec '25
Commercial Operations
16.21
Research and Development Operations
0.59
Total
16.8

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
31.9817.970.510.10.060
Total Debt
52.9334.832.191.270.541.1
Net Cash (Debt)
-20.96-16.86-1.67-1.17-0.49-1.1
Net Cash Growth
------
Net Cash Per Share
-8.20-8.96-3.00-9.18-11.15-

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-35.08-22.59-5.79-0.98-1.57-1.59
Capital Expenditures
-0.29-0.1----
Free Cash Flow
-35.38-22.69-5.79-0.98-1.57-1.59
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
75.16%68.94%----
Operating Margin
-154.01%-187.01%----
Pretax Margin
-212.90%-301.91%----
Profit Margin
-186.23%-257.93%----
FCF Margin
-127.71%-135.09%----

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3.435.70----